Livdelzi® (seladelpar)
for Primary Biliary Cholangitis
Livdelzi (seladelpar) is an oral medication used to treat primary biliary cholangitis (PBC) in adults. It is taken with ursodeoxycholic acid (UDCA) for patients who have not responded well to UDCA, or alone for those who cannot tolerate UDCA. Livdelzi works by activating specific receptors that regulate metabolic and liver disease pathways, including bile acid synthesis, inflammation, fibrosis, and lipid metabolism. It helps reduce bile acid production and prevent liver damage from bile acid buildup.
